Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 4Neoplasms 3Lymphoma, T-Cell, Peripheral 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, B-Cell 2Recurrence 1Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

uridine triacetate 1spartalizumab 1denileukin diftitox 1Interleukin-2 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Drug-Related Side Effects and Adverse Reactions × denileukin diftitox × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡